HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nov. 4, 2005--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it has filed further proposals with the FDA concerning meeting requirements for approval of the Company’s PMA for its proprietary urine NTP test kit. The urine NTP test kit is based on the Company’s AlzheimAlert(TM) testing technology which provides a valuable aid to physicians in the diagnosis of Alzheimer’s disease.
